Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.03%
#3 CoW Protocol CoW Protocol +41.64%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +23.75%
#6 Walrus Walrus +22.87%
#7 Enso Enso +21.16%
#8 Tutorial Tutorial +17.28%
#9 Codatta Codatta +16.14%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Kedudukan dalam Saham #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Harga Saham
$0.30221445
Disegerakkan terakhir: 2023-05-22
Modal Pasaran
$2.49M
Perubahan (1 hari)
-0.10%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Lysogene S.A. (LYS)

Kategori

Healthcare
Hasil untuk Lysogene S.A. (LYS)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Lysogene S.A., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Lysogene S.A. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE